You are here:

Archived: Olanzapine (Zyprexa®)


Following a full submission.

Olanzapine for Intramuscular use is accepted for use within NHS Scotland for the control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate.

Intramuscular olanzapine has been shown to be at least as clinically and cost-effective as haloperidol or lorazepam in treating agitation and other symptoms associated with acute schizophrenia and bipolar disorder. Both the clinical and the economic case are limited by the entry criteria for trials, which effectively restricted entry to moderately agitated patients and excluded those who were severely agitated. However, the difficulties in conducting research in this clinical situation are recognised.

Drug Details

Drug Name: Olanzapine (Zyprexa®)
SMC Drug ID: 106/04
Manufacturer: Eli Lilly and Company Ltd
Indication: Acute agitation in schizophrenia or acute mania
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Full submission
Status: Accepted
Date Advice Published: 12 July 2004

Current Advice

Full submission 12 July 2004

Archived Advice

Full submission 10 May 2004